HaematologicaPub Date : 2025-07-17DOI: 10.3324/haematol.2025.288033
Alison J Moskowitz
{"title":"Fit, unfit, or frail? Now easier to tell for Hodgkin lymphoma.","authors":"Alison J Moskowitz","doi":"10.3324/haematol.2025.288033","DOIUrl":"https://doi.org/10.3324/haematol.2025.288033","url":null,"abstract":"Not available.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"109 1","pages":""},"PeriodicalIF":10.1,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HaematologicaPub Date : 2025-07-17DOI: 10.3324/haematol.2025.287524
Ingram Iaccarino,Thomas Beder,Sarah Reinke,Peter Borchmann,Bastian Von Tresckow,Michael Altenbuchinger,Wolfram Klapper
{"title":"Long non-coding RNA LINC00926 is a biomarker for naïve B-cells with prognostic value in advanced stage classic Hodgkin Lymphoma.","authors":"Ingram Iaccarino,Thomas Beder,Sarah Reinke,Peter Borchmann,Bastian Von Tresckow,Michael Altenbuchinger,Wolfram Klapper","doi":"10.3324/haematol.2025.287524","DOIUrl":"https://doi.org/10.3324/haematol.2025.287524","url":null,"abstract":"Not available.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"29 1","pages":""},"PeriodicalIF":10.1,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HaematologicaPub Date : 2025-07-17DOI: 10.3324/haematol.2025.287897
Isaac Shamie, Meghan Bliss-Moreau, Jamie Casey Lee, Ronald Mathieu, Harold M Hoffman, Bob Geng, Nathan E Lewis, Yanfang Peipei Zhu, Ben A Croker
{"title":"Comparative single-cell lineage bias in human and murine hematopoietic stem cells.","authors":"Isaac Shamie, Meghan Bliss-Moreau, Jamie Casey Lee, Ronald Mathieu, Harold M Hoffman, Bob Geng, Nathan E Lewis, Yanfang Peipei Zhu, Ben A Croker","doi":"10.3324/haematol.2025.287897","DOIUrl":"https://doi.org/10.3324/haematol.2025.287897","url":null,"abstract":"<p><p>The commitment of hematopoietic stem cells (HSC) to myeloid, erythroid, and lymphoid lineages is influenced by microenvironmental cues, and governed by cell-intrinsic and epigenetic characteristics that are unique to the HSC population. To investigate the nature of lineage commitment bias in human HSC, mitochondrial single cell (sc) ATAC-Sequencing (mtscATAC-Seq) was used to identify somatic mutations in mitochondrial DNA to act as natural genetic barcodes for tracking the ex vivo differentiation potential of HSC to mature cells. Clonal lineages of human CD34+ cells and their mature progeny were normally distributed across the hematopoietic lineage tree without evidence of significant skewing. To investigate commitment bias in vivo, mice were transplanted with limited numbers of long-term HSC (LT-HSC). Variation in the ratio of myeloid and lymphoid cells between donors, although suggestive of a skewed output, was not altered by increasing numbers of LT-HSC. These data suggest that the variation in myeloid and lymphoid engraftment is a stochastic process dominated by the irradiated recipient niche with minor contributions from the cell-intrinsic lineage bias of LT-HSC.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Changing donors improves outcomes of second transplantation in patients who experienced graft failure after first allogeneic stem cell transplantation.","authors":"Rui Ma,Xiao-Yu Zhu,Yue Lu,Jia Chen,Li Xuan,Hai-Long Yuan,Yang Cao,Wei-Jie Cao,Xiao-Sheng Fang,Kou-Rong Miao,Xiao-Xia Hu,Hai Yi,Yan-Min Zhao,Yuan-Bin Wu,Ting Yang,Hong-Tao Wang,Yue Yin,Zhong-Ming Zhang,Xiao-Hui Zhang,Lan-Ping Xu,Yu Wang,Kai-Yan Liu,Xiao-Jun Huang,Yu-Qian Sun","doi":"10.3324/haematol.2025.287554","DOIUrl":"https://doi.org/10.3324/haematol.2025.287554","url":null,"abstract":"A second transplantation is almost the only salvage for patients encountering graft failure (GF) following the first allogeneic stem cell transplantation. However, there were no standard protocols for second transplantations, and the role of changing donors remained controversial. We retrospectively studied 272 consecutive patients from 18 Chinese centers undergoing second transplantations due to GF, aiming to assess the impact of changing donors and factors affecting second transplantation outcomes. The primary endpoint was neutrophil engraftment. Other endpoints included platelet engraftment, graft versus host disease (GVHD), transplant related mortality (TRM), relapse, and survival. Of the 272 patients, 193 (71.0%) patients experienced primary GF, and 70.6% (192) used a different second donor. Neutrophil engraftment was achieved in 218 (86.3%) patients by d28, and platelet engraftment was achieved in 164 (70.0%) patients by d100. The 3-year cumulative incidence of acute GVHD, chronic GVHD, relapse, and TRM were 43.5%, 27.8%, 15.6%, and 44.6%, respectively. The 1-year and 3-year overall survival (OS) were 56.1% and 49.5%, respectively. Compared to using the same donor, changing donors significantly improved neutrophil (92.4% vs 71.4%, p.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"12 1","pages":""},"PeriodicalIF":10.1,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HaematologicaPub Date : 2025-07-10DOI: 10.3324/haematol.2024.287124
Vesna S Stanulović,Sarah Binhassan,Budoor A Jaber,Shimaa Alazmi,Fatma M B Saleman,Sandeep Potluri,Guy Pratt,Christian Ludwig,Douglas G Ward,Maarten Hoogenkamp
{"title":"PHF6 interacts with the LMO2 complex in T-cell acute lymphoblastic leukemia.","authors":"Vesna S Stanulović,Sarah Binhassan,Budoor A Jaber,Shimaa Alazmi,Fatma M B Saleman,Sandeep Potluri,Guy Pratt,Christian Ludwig,Douglas G Ward,Maarten Hoogenkamp","doi":"10.3324/haematol.2024.287124","DOIUrl":"https://doi.org/10.3324/haematol.2024.287124","url":null,"abstract":"The transcriptional mediator LIM domain only 2 (LMO2) forms a large multi-protein complex together with TAL1/LYL1, HEB/E2A, LDB1 and GATA. This complex regulates transcription from the onset of hematopoietic development and during differentiation. Chromosomal rearrangements involving LMO2 and TAL1 are causative for T-cell lymphoblastic leukemia (TALL). We have identified Plant Homeodomain (PHD)-like Finger 6 (PHF6) as a new LMO2 interacting factor. Somatic mutations in PHF6 have been found to occur in several types of leukemia. We show that PHF6 interacts with LMO2 as a part of the TAL1, GATA2, LDB1 complex in T-ALL and binds to the DNA. These findings show that PHF6 associates with the TAL1/LMO2/LDB1/GATA2 complex and regulates genes that have a major role in blood development, such as SPI1 (PU.1).","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"191 1","pages":""},"PeriodicalIF":10.1,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144594046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HaematologicaPub Date : 2025-07-10DOI: 10.3324/haematol.2025.287547
Mohammad Alhomoud,Rahma Ibrahim,Michelle Demetres,Kai Rejeski,Michael Scordo,Roni Shouval,Tobias Tix,Jeremie Martinet,Michelle Foley,Alexandra Gomez-Arteaga,Tsiporah Shore,Paul Pagnini,Mahmoud Aljurf,Monica L Guzman,Silvia Formenti,Joachim Yahalom,Koen Van Besien,Brandon S Imber,Zhengming Chen,Samuel Yamshon
{"title":"Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis.","authors":"Mohammad Alhomoud,Rahma Ibrahim,Michelle Demetres,Kai Rejeski,Michael Scordo,Roni Shouval,Tobias Tix,Jeremie Martinet,Michelle Foley,Alexandra Gomez-Arteaga,Tsiporah Shore,Paul Pagnini,Mahmoud Aljurf,Monica L Guzman,Silvia Formenti,Joachim Yahalom,Koen Van Besien,Brandon S Imber,Zhengming Chen,Samuel Yamshon","doi":"10.3324/haematol.2025.287547","DOIUrl":"https://doi.org/10.3324/haematol.2025.287547","url":null,"abstract":"Bridging radiation therapy (BRT) is increasingly utilized prior to CART19 in NHL patients. However, its impact on CART19 outcomes is not established. We conducted a systematic review and meta-analysis to estimate the safety and efficacy of BRT prior to CART19 therapy. A comprehensive search was performed in databases from inception to October 2024. We identified 18 studies encompassed 538 adult NHL patients who received BRT prior to commercial CART19. Random-effect models were applied to explore meta-analysis outcomes. DLBCL was the most common diagnosis (73%), and axicabtagene ciloleucel was the most utilized product (67%). Bulky disease was present in 37%. Median BRT dose was 30 Gy delivered comprehensively to all sites of PET avid disease in 76% of cases. ORR to CART19 was 78.9%. At 1 year, PFS was 54.6% while OS was 71.2%. All-grade CRS was 80% while all-grade ICANS was 39.4%. Grade 3/4 CRS was 3.6% and grade 3/4 ICANS was 10.6%. Sensitivity analyses including studies with bulky disease and excluding studies with patients who also received systemic bridging therapy, demonstrated consistent results compared to the main study findings. Sub-group meta-regression showed similar results in studies that utilized BRT only compared to studies that utilized combined-modality treatment. In conclusion, this metaanalysis found that BRT use prior to CART19, whether as a standalone approach or in combination with systemic therapy, does not increase toxicity or compromise the efficacy of CART19 therapy in NHL. Furthermore, use of BRT is associated with low rate of CRS, even in patients with bulky disease.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"21 1","pages":""},"PeriodicalIF":10.1,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144594091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}